Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter

Sunshine Biopharma Inc.

2025-Q3 EPS reported -$13.61 vs consensus -$0.13 ▼ miss (-10164.0%)

Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.
Q3 net loss $(1.20M) compared to $(0.65M) in Q3 2023, a YoY increase of 84%.
YTD net loss $(2.98M) vs $(3.26M) in prior year period, an improvement of 9%.
Shareholders' equity grew 18% to $25.04M from $21.21M at Dec 31, 2023.
Growth driven by new product launches and expanded marketing via Canadian subsidiary Nora Pharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.